Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07581886

sACB vs cACB in TKA

This study compares the analgesic efficacy of single-dose adductor canal block (sACB) versus continuous-dose adductor canal block (cACB) for postoperative pain management in total knee replacement patients. To ensure a high level of clinical accuracy, the investigation specifically focuses on a cACB cohort where ultrasound confirmation ensures the catheter remains correctly positioned for a full 48 hours. Participants are assigned to groups using a 1:1 randomization protocol via computer-generated tables to eliminate selection bias. Clinical consistency is maintained by using identical pharmacological agents across both groups: 0.5% Heavy Bupivacaine for spinal anesthesia and 0.5% ropivacaine with 1:200,000 epinephrine for the nerve block itself. Furthermore, both groups adhere to a standardized multimodal analgesic schedule to control for external variables. In the cACB group, intravenous patient-controlled analgesia (IV PCA) serves as a designated rescue therapy should the catheter fail. The primary technical evaluation occurs 48 hours post-surgery, utilizing ultrasound to verify catheter placement and quantify pain levels. Beyond immediate recovery, the study evaluates long-term success through Patient-Reported Outcome Measures (PROMs) at a 12-week follow-up, focusing on functional restoration and the patient's overall quality of life. By isolating the variable of catheter stability, the research aims to provide a definitive comparison of whether the continuous delivery of local anesthetic offers a statistically significant clinical advantage over a single-dose administration in the context of modern orthopedic recovery protocols.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 40-80 yrs
  • Scheduled for unilateral total knee arthroplatsy
  • ASA I-III
  • BMI 18-35 kg/㎡
  • Able to read and understand consent form

Exclusion criteria

  • Allergy to local anesthetics
  • Infection at the block site
  • History of neuropathy or peripheral nerve disease
  • Coagulation disorders or use of anticoagulants (if discontinuation is not possible)
  • Communication disorders or cognitive impairment
  • Chronic opioid use (≥30 MME/day, 3 months or more)
  • Severe chronic pain (NRS ≥7/10, 3 months or more)
  • Renal impairment (eGFR <30 mL/min/1.73m²)
  • Hepatic impairment (Child-Pugh C)
  • Blood coagulation disorders
  • Pregnancy

Treatment and study plan

Continuous ACB

Procedure

Adductor canal block, a lower extremity nerve block technique for postoperative pain control, is performed under ultrasound guidance for patients undergoing total knee arthroplasty, and is carried out by inserting a catheter. The catheter is connected to a PCA pump following insertion, with a continuous infusion rate for two days post-surgery.

Single-shot ACB

Procedure

Adductor canal block, a lower extremity nerve block technique for postoperative pain control, is performed under ultrasound guidance for patients undergoing total knee arthroplasty, and is carried out by a single-shot local anesthetic administration.

Primary outcomes

  1. postoperative pain score at rest (Area Under Curve, AUC)

    Time frame: postoperative 48 hours

    48-hour postoperative pain score at rest (Area Under Curve, AUC) using NRS.

Study contacts

Contact information is provided by the study sponsor or research team.

eunjung Kim

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Official study title

Comparison of Single-shot vs. Continuous Adductor Canal Block Analgesic Effects With Catheter Positioning Confirmation in Total Knee Arthroplasty: a Double-blinded Prospective Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 12, 2026
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.